Anti-Human CD47 (Clone B6H12) - Purified in vivo GOLD™ Functional Grade
| Code | Size | Price |
|---|
| LEI-C2202-1mg | 1 mg | £175.00 |
Quantity:
| LEI-C2202-5mg | 5.0 mg | £380.00 |
Quantity:
| LEI-C2202-25mg | 25 mg | £1,014.00 |
Quantity:
| LEI-C2202-50mg | 50 mg | £1,556.00 |
Quantity:
| LEI-C2202-100mg | 100 mg | £2,159.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 κ
Antibody Clonality: Monoclonal
Antibody Clone: B6H12
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Functional Study
- In Vivo Assay
- Neutralisation
Shipping:
2-8°C
Storage:
This Low Endotoxin Functional Formulation conjugate is stable when stored at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
CD47 is expressed on leukocytes, platelets, erythrocytes, epithelial cells, endothelial cells, fibroblasts, and is overexpressed in ovarian cancer, as well as many different tumor cells.
Concentration:
1.0 - 5.0 mg/ml
Conjugate/Tag/Label:
Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Purified Recombinant Human CD47 (>98%)
Long Description:
CD47 is a 50 kD transmembrane protein receptor to the Ig superfamily that can manifest in four isoforms, differing only in the length of their cytoplasmic tail. CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion, and migration, and plays a key role in immune and angiogenic responses. CD47 was first identified as a tumor antigen on human ovarian cancer and its expression has subsequently been found on multiple human tumor types such as acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin?s lymphoma (NHL), multiple myeloma (MM), bladder cancer, and pediatric and adult brain tumors. CD47 interacts with membrane integrins, TSP-1, and SIRPα. The CD47/SIRPα interaction results in the inhibition of phagocytosis by macrophages thus, allowing cancer cells to multiply unchecked. Anti-CD47 antibody is a potential therapeutic target in a variety of cancers and for the treatment of pulmonary fibrosis. Anti-CD47 antibody treatment not only facilitates macrophage phagocytosis of cancer, but also promotes the activation of cancer-specific lymphocytes by acting as a beacon, flagging cancer cells which now display altered proteins to which the immune system can react.
NCBI Gene:
961
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
CD47